A Phase 2/3 interventional study of Tirzepatide and Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) in Type 1 Diabetes, Type 1 Diabetes Mellitus and T1D, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Phase 2/3, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre — 7 open to participants now, 7 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · McGill University Health Centre/Research Institute of the McGill University Health Centre.
Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, this one is the 2nd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 5 in phase 2/3, and was the 14th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →7 of the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre are open now, in 2 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 6 · Phase 4 1
First in 2016; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 105 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 34 across the 12 interventional studies, 380 across the 3 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
1 of the studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 15 studies in Diabetes Mellitus, Type 1 by McGill University Health Centre/Research Institute of the McGill University Health Centre, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study is testing whether a weekly medication called tirzepatide can help adults with type 1 diabetes use their insulin pump more easily, specifically by reducing or eliminating the need to count carbohydrates at meals.
People with type 1 diabetes must take insulin for life, and even with advanced insulin pumps and continuous glucose monitors, many still struggle to keep blood sugar within the target range. One of the biggest challenges is carbohydrate counting, which requires estimating the amount of carbohydrates in every meal to give the correct insulin dose.
Tirzepatide is a medication currently approved for type 2 diabetes and weight management. Early research suggests it may also help people with type 1 diabetes by lowering appetite, slowing digestion, reducing insulin needs, and smoothing after-meal blood sugar rises.
This study will include 105 adults with type 1 diabetes at centers in Canada and Switzerland. Everyone will use the Tandem Control-IQ insulin pump with a Dexcom G7 continuous glucose monitor. Participants are randomly assigned to one of two groups:
Tirzepatide group:
Participants receive weekly tirzepatide injections. After the dose is gradually increased over 12 weeks, they will eventually try using their insulin pump without entering carbohydrate amounts at meals.
Control group:
Participants continue their usual therapy and keep counting carbohydrates for their mealtime insulin doses.
The main goal of the study is to learn whether people taking tirzepatide can safely maintain good blood sugar control without counting carbs, compared with standard care. All participants will attend several clinic visits and share their glucose, insulin, and health data throughout the 32-week trial. Some centers will also conduct heart/fitness, or body-composition tests.
As with any medication, tirzepatide may cause side effects such as nausea, vomiting, diarrhea, or decreased appetite. Rare but serious risks like gallbladder disease or pancreatitis are also monitored. Pregnancy must be avoided during the trial.
Overall, this study aims to understand whether adding tirzepatide to automated insulin delivery can simplify diabetes management, reduce burden, and maintain safe and effective glucose control for adults living with type 1 diabetes.
Current diabetes technology, including hybrid automated insulin delivery systems like the Tandem Control-IQ paired with the Dexcom G7 continuous glucose monitor, improves glucose control but still relies heavily on patients entering carbohydrate amounts before eating, a task that is difficult, error-prone, and often stressful.
Tirzepatide, which is approved for type 2 diabetes and weight management, works by slowing digestion, lowering appetite, reducing insulin requirements, and improving after-meal glucose spikes, and early evidence suggests it may offer similar benefits in type 1 diabetes. This study is designed to determine whether adding once-weekly tirzepatide injections to a commercially available automated insulin delivery system can make diabetes management easier for adults with type 1, particularly by reducing or eliminating the need to count carbohydrates at meals.
In this 32-week trial, 105 adults will be randomly assigned to receive tirzepatide or no tirzepatide while all participants use the Control-IQ system. Those receiving tirzepatide will gradually increase their dose over 12 weeks, continue counting carbohydrates until week 26, and then stop announcing meals entirely for the final 6 weeks, while the control group will count carbohydrates throughout.
Across the study, participants will attend scheduled clinic visits, complete remote follow-ups, undergo laboratory tests, and, depending on the site, may complete heart function tests, body-composition scans, fitness testing, or gastric emptying assessments. Researchers will compare glucose control, insulin needs, weight, metabolic markers, meal patterns, and patient-reported outcomes between groups, with the primary goal of determining whether glucose management without carbohydrate counting is not worse than (non-inferior to) standard carbohydrate counting.
The study also closely monitors safety, as tirzepatide can cause nausea, vomiting, diarrhea, decreased appetite, and rare complications such as gallbladder disease or pancreatitis. Overall, this research aims to learn whether combining tirzepatide with automated insulin delivery can safely simplify diabetes management, reduce treatment burden, and improve metabolic outcomes for adults living with type 1 diabetes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm receive once-weekly subcutaneous tirzepatide in addition to use of the Tandem Control-IQ insulin pump and Dexcom G7 continuous glucose monitor. Tirzepatide is initiated at 2.5 mg weekly and increased by 2.5 mg every 4 weeks to a target dose of 10 mg weekly or the maximally tolerated dose. Dose escalation may be delayed or reduced if participants experience intolerable gastrointestinal symptoms. During Weeks 1-26, participants continue standard carbohydrate counting for all meals. Beginning in Week 27, participants stop entering carbohydrate amounts into the pump (no meal announcements) for six weeks while continuing tirzepatide at their maintenance dose. Throughout the intervention, participants undergo regular safety assessments, remote glucose data reviews, insulin-pump parameter adjustments as needed, and scheduled in-person visits to monitor metabolic, cardiovascular, and patient-reported outcomes.
Drug: Tirzepatide · Device: Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) · Behavioral: Carbohydrate Counting · Behavioral: No Meal Announcement
Participants randomized to the control arm use the Tandem Control-IQ automated insulin delivery system with the Dexcom G7 continuous glucose monitor, following standard-of-care diabetes management. They continue carbohydrate counting for all meals throughout the 32-week study and deliver prandial insulin boluses based on estimated carbohydrate intake, as is typical for users of hybrid closed-loop systems. No tirzepatide injections are administered. Participants receive the same device training, follow-up schedule, safety monitoring, glucose data reviews, and pump parameter adjustments as the tirzepatide arm. This arm serves as an active comparator, representing current standard therapy for type 1 diabetes with automated insulin delivery and meal announcements.
Device: Tandem Control-IQ Automated Insulin Delivery System (with Dexcom G7 CGM) · Behavioral: Carbohydrate Counting
Tirzepatide, administered as a once-weekly subcutaneous injection, initiated at 2.5 mg and escalated in 2.5-mg increments every 4 weeks to a target of 10 mg or the maximally tolerated dose, used as an adjunct therapy in adults with type 1 diabetes using the Tandem Control-IQ automated insulin delivery system.
Also known as: Mounjaro
This intervention uses the Tandem t:slim X2 insulin pump with the Control-IQ automated insulin delivery algorithm, integrated with the Dexcom G7 continuous glucose monitor. The system adjusts basal insulin and delivers automated correction boluses based on real-time glucose values. All participants receive standardized training and use this system for the full 32-week study. Rapid-acting insulin compatible with Control-IQ is required. This intervention is distinguished by its use under two different operational strategies: standard carbohydrate counting in the control arm and complete omission of meal announcements during the final 6 weeks in the tirzepatide arm.
Also known as: Control-IQ, Dexcom G7
Participants enter the estimated carbohydrate amount for every meal and snack into the Tandem Control-IQ insulin pump to calculate and deliver prandial insulin boluses. This reflects standard use of hybrid closed-loop systems. The procedure is maintained for the entire 32-week study in the control arm and during Weeks 1-26 in the tirzepatide arm.
Also known as: Meal Announcement
Participants do not enter carbohydrate amounts or announce meals to the Tandem Control-IQ system. The pump operates without user-initiated prandial boluses, relying solely on automated basal adjustments and automated correction boluses. This intervention is implemented only in the tirzepatide arm during Weeks 27-32.
Also known as: Omission of Carbohydrate Counting
Daytime Time-in-Range
The primary outcome is the percentage of daytime hours (06:00-24:00) during which participants' glucose levels, measured by the Dexcom G7 continuous glucose monitor, fall within the target range of 3.9-10.0 mmol/L.
Time frame: During the final 6 weeks of the study
Weight
Change in body weight to assess the effects of tirzepatide on body composition. Weight is measured in kilograms.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study
Height
Change in height to assess the effects of tirzepatide on body composition. Height is measured in meters.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.
Body Mass Index
Change in BMI to assess the effects of tirzepatide on body composition. BMI is measured in kilograms per square meter.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study
Waist circumference
Change in waist circumference to assess the effects of tirzepatide on body composition. Waist circumference is measured in centimetres.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study
Waist-to-Hip Ratio
Change in waist-to-hip ratio to assess the effects of tirzepatide on body composition. Waist-to-Hip Ratio is measured by dividing the waist circumference by the hip circumference. It is unitless.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.
Systolic Blood Pressure
Change in systolic blood pressure to evaluate the cardiovascular effects of tirzepatide. Systolic blood pressure is measured in millimetres of mercury.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.
Diastolic Blood Pressure
Change in diastolic blood pressure to evaluate the cardiovascular effects of tirzepatide. Diastolic blood pressure is measured in millimetres of mercury.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.
Resting Heart Rate
Change in resting heart rate to assess the cardiovascular effects of tirzepatide. Resting heart rate is measured in beats per minute.
Time frame: At enrollment, Week 8, Week 16, Week 24, and Week 32, At Week 8 and Week 16 post-study.
Insulin-related measures
Daily insulin requirements, including basal insulin, bolus insulin, and total insulin units per day, recorded through the insulin pump. Total insulin use normalized to body weight (units/kg/day) to assess treatment-related changes in insulin sensitivity. Carbohydrate amounts entered for bolus dosing (control arm and Weeks 1-26 of tirzepatide arm).
Time frame: Continuously from randomization through Week 32, with primary analysis focused on Weeks 27-32, At Week 8 and Week 16 post-study.
Glucose outcomes
Percentage of CGM readings within 3.9-10.0 mmol/L, 3.9-7.8 mmol/L, \<3.9 mmol/L, \<3.0 mmol/L, \>10.0 mmol/L, and \>13.9 mmol/L, as well as mean glucose, glucose standard deviation, and glucose coefficient of variation.
Time frame: Continuously collected from randomization through Week 32, with key comparisons during Weeks 23-26 and Weeks 27-32, At Week 8 and Week 16 post-study.
Glycated Hemoglobin (HbA1c)
Change in glycated hemoglobin (HbA1c) to assess overall glycemic control over the study period.
Time frame: At enrollment, mid-study at Week 16, and at the end-of-study visit at Week 32, At Week 8 and Week 16 post-study.
Estimated Glomerular Filtration Rate
Changes in estimated glomerular filtration rate. eGFR is measured in millilitres/minute/body surface.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Serum Creatinine
Changes in serum creatinine. Serum creatinine is measured in umol/L.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Albumin-to-Creatinine Ratio
Changes in urinary albumin-to-creatinine ratio. Urinary albumin-to-creatinine ratio is measured in mg/mmol.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Lipid Panel (Total Cholesterol, LDL-C, HDL-C, Triglycerides)
Changes in fasting lipid profile to assess cardiometabolic effects of tirzepatide. All components of the lipid panel are measured in millimole/liter.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Liver Function Markers (Alanine transaminase, Alkaline phosphatase)
Changes in liver enzymes to monitor hepatic safety. Hepatic enzymes are measured in Units per Litre.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Liver Function Markers (Bilirubin)
Changes in bilirubin to monitor hepatic safety. Bilirubin (Total, Direct, Indirect) are measured in micromoles per litre.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Cardiac Biomarkers (NT-proBNP)
Serum biomarker used to assess cardiac strain, providing insights into the broader metabolic effects of tirzepatide. NT-proBNP is measured in picograms per millilitre.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Inflammatory Biomarkers (hs-CRP)
Serum biomarkers used to assess inflammation providing insights into the broader metabolic effects of tirzepatide. hs-CRP is measured in milligrams per litre.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
Inflammatory Biomarkers (IL-6)
Serum biomarkers used to assess inflammation, providing insights into the broader metabolic effects of tirzepatide. IL-6 is measured in picograms per millilitre.
Time frame: At enrollment, Week 16, and Week 32, At Week 8 and Week 16 post-study.
C-Peptide
Change in fasting C-peptide to assess residual β-cell function.
Time frame: At enrollment and at Week 32, At Week 8 and Week 16 post-study.
Carotid-Femoral Pulse Wave Velocity and Pulse Wave Analysis
Measures of arterial stiffness and central blood pressure, used to evaluate vascular effects of treatment.
Time frame: At enrollment and at Week 32 (site-dependent).
DXA Body Composition
Whole-body DXA assessment of fat mass, lean mass, visceral fat, and bone density.
Time frame: At enrollment and at Week 32 (site-dependent).
Echocardiogram (Diastolic Function Parameters)
Assessment of cardiac structure and diastolic function, including E/A ratio, e', E/e', and left atrial volume.
Time frame: At enrollment and at Week 32 (site-dependent).
VO₂-max Test
Measurement of maximal oxygen consumption to evaluate cardiopulmonary fitness.
Time frame: At enrollment and at Week 32 (site-dependent).
Quality-of-Life Measures (Diabetes Distress Scale)
Changes in the standardized Diabetes Distress Scale using the validated questionnaire. A participant's score is measured as the sum of responses to the appropriate items divided by the number of items in that scale. A mean item score 2.0 - 2.9 is considered moderate distress, and a mean item score \> 3.0 is considered high distress.
Time frame: At enrollment and at Week 32.
Quality-of-Life Measures (Hypoglycemia Fear Survey II)
Changes in the standardized Hypoglycemia Fear Survey II using the validated questionnaire. HFS-II Total Score range: 0-132. Higher scores on the total HFS-II indicate a greater fear of hypoglycemia. The questionnaire does not have pre-defined cut-off scores for diagnostic categories; instead, the scores are used to measure the level of fear.
Time frame: At enrollment and at Week 32.
Quality-of-Life Measures (Three Factor Eating r18 Questionnaire)
Changes in the standardized Three Factor Eating Questionnaire scores. The three-factor eating questionnaire provides a score from 0 to 100 for cognitive restraint, uncontrolled eating, and emotional eating. Higher scores indicate greater cognitive restraint, uncontrolled eating, and emotional eating.
Time frame: At enrollment and at Week 32.
Gastric Emptying via [13C] Acetate Breath Test
Rate of gastric emptying assessed by breath ¹³CO₂ appearance following standardized test meal.
Time frame: At enrollment (or training visit) and at Week 32 (site-dependent).
Blood Glucagon Response to Standardized Meal
Change in glucagon concentrations following ingestion of a standardized liquid meal.
Time frame: At enrollment and at Week 32 (site-dependent).
Meal Tracking Using Keenoa or MyFood24
Assessment of caloric intake and macronutrient composition via 3-day dietary records.
Time frame: Prior to randomization, during Week 16, and during Week 32.
Severe hypoglycemia
Episode requiring the assistance of another person, due to altered consciousness, to administer carbohydrates, glucagon, or other resuscitative actions.
Time frame: From the time the participant signs informed consent until the end of study participation at Week 32, with additional safety follow-up at Week 8 and Week 16 post-study.
Diabetic Ketoacidosis
Clinical episode characterized by hyperglycemia/euglycemia, ketonemia or ketonuria, metabolic acidosis, and associated symptoms such as nausea, vomiting, abdominal pain, rapid breathing, or altered consciousness. Events requiring emergency evaluation, intravenous fluids, or hospital treatment will be recorded as DKA. All episodes will be assessed for severity, timing, precipitating factors, and their relationship to study interventions, including tirzepatide use and automated insulin delivery performance.
Time frame: From the time the participant signs informed consent until the end of study participation at Week 32, with additional safety follow-up at Week 8 and Week 16 post-study.
Gastrointestinal and related side effects
Nausea Vomiting Abdominal pain Diarrhea Constipation Liver profile changes Gallbladder disease Acute pancreatitis Other related side effects
Time frame: From the time the participant signs informed consent until the end of study participation at Week 32, with additional safety follow-up at Week 8 and Week 16 post-study.
Plan to share: Yes — De-identified individual participant data may be shared with qualified researchers after completion of the trial and publication of the primary results. Shared data may include de-identified demographic variables, glucose and insulin delivery data, laboratory results, questionnaire scores, and device-based assessments collected during the study. All data will be reviewed to minimize re-identification risk in accordance with Canadian and Swiss privacy regulations. Researchers must submit a scientifically valid proposal and sign a data use agreement. Requests will be reviewed by the study team, and approved data will be provided through a secure transfer process.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: IPD will be made available beginning 12 months after publication of the primary results and for a period of five years thereafter.
Access criteria: Researchers must submit a scientifically valid proposal and sign a data use agreement.
Started May 2026 (actual). Primary completion is estimated for Jan 2028, 20 months after the start.
Of 19 phase 2/3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 20 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
McGill University Health Centre/Research Institute of the McGill University Health Centre →